IDYA News and Press, IDEAYA Biosciences Inc. From 08/10/23

2023-08-10 10:54:17 ET IDEAYA Biosciences press release ( NASDAQ: IDYA ): Q2 GAAP EPS of -$0.50 beats by $0.06 . Revenue of $3.54M (-68.8% Y/Y) misses by $0.86M . Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of J...

IDEAYA Biosciences, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Strong balance sheet of $510.1 million of cash, cash equivalents and marketable securities as of June 30, 2023 anticipated to fund operations into 2027 I...

IDEAYA and Amgen Achieve First-Patient-In for Clinical Evaluation of IDE397 (MAT2A) and AMG 193 (PRMT5(MTA)) Combination in MTAP(-/-) Tumors PR Newswire -­ First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperativ...

IDEAYA Biosciences to Participate in Upcoming August 2023 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , Aug. 1, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...

2023-07-05 17:32:16 ET Gainers: Cardlytics, Inc. ( NASDAQ: CDLX ) +9% . Autolus Therapeutics  ( AUTL ) +5% . Omeros ( OMER ) +4% . Arrival ( ARVL ) +3% . Nkarta ( NKTX ) +3% . Losers: IDEAYA Biosciences ( IDYA ...

IDEAYA Announces First Reported Case of Uveal Melanoma Patient Spared Enucleation in Phase 1 Neoadjuvant IST with Darovasertib Monotherapy PR Newswire Eye preservation reported for the first UM patient treated with darovasertib monotherapy under the amended IST protocol enabli...

IDEAYA Announces Selection of IDE397 Phase 2 Monotherapy Expansion Dose For Global Enrollment Targeting High Priority MTAP-Deletion Solid Tumor Types PR Newswire Phase 2 monotherapy expansion dose selected for enrollment in high priority MTAP-deletion solid tumor types –...

2023-06-08 17:27:08 ET Summary Today, we take our first in-depth look at a developmental concerned called Ideaya Biosciences, Inc. Ideaya Biosciences is moving forward a diverse pipeline of drug candidates based on its focus on synthetic lethality. An investment analysis follo...

IDEAYA Biosciences to Participate in Upcoming June 2023 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , May 30, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and ...

IDEAYA Announces IND Clearance Enabling Phase 1/2 Clinical Trial for Combination of IDE397 and AMG 193 in MTAP-Deletion Solid Tumors PR Newswire IDE397 (MAT2A) and AMG 193 (PRMT5) combination being evaluated in an Amgen-sponsored Phase 1/2 clinical trial in MTAP-deletion solid...